Gene Logic and Organon Enter Collaboration to Find New Therapeutic Applications for Clinical Drug Candidates

GAITHERSBURG, Md. & OSS, The Netherlands, Apr 21, 2006 (BUSINESS WIRE) — Gene Logic Inc. (NASDAQ:GLGC) and Organon announced today that they have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon has previously discontinued clinical development. Under the terms of the agreement, Gene Logic will seek new therapeutic uses for Organon compounds.

Source: Gene Logic